Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 17/20 | 0.60 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.60 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.59 |
| ▸ | CSF1R | P07333 | 2/20 | 0.59 |
| ▸ | PIM1 | P11309 | 2/20 | 0.59 |
| ▸ | CLK2 | P49760 | 2/20 | 0.59 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.59 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.59 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.59 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.59 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.59 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.59 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.59 |
| ▸ | INSR | P06213 | 1/20 | 0.59 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.59 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.59 |
| ▸ | MELK | Q14680 | 1/20 | 0.59 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.59 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.59 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3156222 | 0.96 | PARP1 (0.62) | PARP1PARP2MAP4K4CSF1RPIM1 | |
| SCHEMBL3159180 | 0.96 | PARP1 (0.61) | PARP1PARP2MAP4K4CSF1RPIM1 | |
| SCHEMBL3150588 | 0.95 | PARP1 (0.61) | PARP1PARP2MAP4K4CSF1RPIM1 | |
| SCHEMBL3165660 | 0.84 | PARP1 (0.72) | PARP1PARP2MAP4K4PIM1CLK2 | |
| SCHEMBL3164686 | 0.83 | PARP1 (0.63) | PARP1PARP2MAP4K4CSF1RPIM1 | |
| SCHEMBL3150584 | 0.83 | PARP1 (0.71) | PARP1PARP2MAP4K4PIM1CLK2 | |
| SCHEMBL3159109 | 0.82 | PARP1 (0.62) | PARP1PARP2DHODH | |
| SCHEMBL2296206 | 0.80 | PARP1 (0.57) | PARP1PARP2MAP4K4CSF1RPIM1 | |
| SCHEMBL3159337 | 0.80 | PARP1 (0.70) | PARP1PARP2DHODH | |
| SCHEMBL3159349 | 0.80 | PARP1 (0.70) | PARP1PARP2DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966157-B1 | SUBSTITUTED 1H-BENZIMIDAZOLE-4-CARBOXAMIDES ARE POTENT PARP INHIBITORS | ABBOTT LAB (US) | 2010-03-24 | — | — | EP | claimed |
| US-7595406-B2 | Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors | ABBOTT LABORATORIES INC. (US) | 2009-09-29 | — | — | US | claimed |
| US-7462724-B2 | Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors | ABBOTT LABORATORIES (US) | 2008-12-09 | — | — | US | claimed |
| EP-1966157-A2 | SUBSTITUTED 1H-BENZIMIDAZOLE-4-CARBOXAMIDES ARE POTENT PARP INHIBITORS | Abbott Laboratories (US) | 2008-09-10 | — | — | EP | claimed |
| US-20070270476-A1 | SUBSTITUTED 1H-BENZIMIDAZOLE-4-CARBOXAMIDES ARE POTENT PARP INHIBITORS | ABBVIE INC. | 2007-11-22 | — | — | US | claimed |
| WO-2007059230-A2 | SUBSTITUTED 1H-BENZIMIDAZOLE-4-CARBOXAMIDES ARE POTENT PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2007-05-24 | — | — | WO | claimed |
| US-20070112047-A1 | SUBSTITUTED 1H-BENZIMIDAZOLE-4-CARBOXAMIDES ARE POTENT PARP INHIBITORS | ABBVIE INC. | 2007-05-17 | — | — | US | claimed |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2022-09-20 | — | — | US | disclosed |
| US-20190183843-A9 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS, INC. (CA) | 2019-06-20 | — | — | US | disclosed |
| US-20190175541-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS, INC. (CA) | 2019-06-13 | — | — | US | disclosed |
| US-20190091195-A1 | USE OF DIANHYDROGALACTITOL AND DERIVATIVES THEREOF IN THE TREATMENT OF GLIOBLASTOMA, LUNG CANCER, AND OVARIAN CANCER | DEL MAR PHARMACEUTICALS (CA) | 2019-03-28 | — | — | US | disclosed |
| US-20180071244-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS INC (CA) | 2018-03-15 | — | — | US | disclosed |
| EP-1966157-B1 | SUBSTITUTED 1H-BENZIMIDAZOLE-4-CARBOXAMIDES ARE POTENT PARP INHIBITORS | ABBOTT LAB (US) | 2010-03-24 | — | — | EP | disclosed |
| US-7595406-B2 | Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors | ABBOTT LABORATORIES INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-7462724-B2 | Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors | ABBOTT LABORATORIES (US) | 2008-12-09 | — | — | US | disclosed |
| EP-1966157-A2 | SUBSTITUTED 1H-BENZIMIDAZOLE-4-CARBOXAMIDES ARE POTENT PARP INHIBITORS | Abbott Laboratories (US) | 2008-09-10 | — | — | EP | disclosed |
| US-20070270476-A1 | SUBSTITUTED 1H-BENZIMIDAZOLE-4-CARBOXAMIDES ARE POTENT PARP INHIBITORS | ABBVIE INC. | 2007-11-22 | — | — | US | disclosed |
| WO-2007059230-A2 | SUBSTITUTED 1H-BENZIMIDAZOLE-4-CARBOXAMIDES ARE POTENT PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20070112047-A1 | SUBSTITUTED 1H-BENZIMIDAZOLE-4-CARBOXAMIDES ARE POTENT PARP INHIBITORS | ABBVIE INC. | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190175541-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | PARP1 418/4885PARP2 422/4885MAP4K4 1643/4885 |
| US-20070112047-A1 | SUBSTITUTED 1H-BENZIMIDAZOLE-4-CARBOXAMIDES ARE POTENT PARP INHIBITORS | PARP1, PARP2, PARP4 | PARP1 1/4885PARP2 2/4885MAP4K4 1244/4885 |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DCK, CDC7, DNMT1 | PARP1 418/4885PARP2 422/4885MAP4K4 1643/4885 |
| US-20180071244-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | PARP1 418/4885PARP2 422/4885MAP4K4 1643/4885 |
| US-20190183843-A9 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | PARP1 418/4885PARP2 422/4885MAP4K4 1643/4885 |
| US-20190091195-A1 | USE OF DIANHYDROGALACTITOL AND DERIVATIVES THEREOF IN THE TREATMENT OF GLIOBLASTOMA, LUNG CANCER, AND OVARIAN CANCER | DDOST, DCLRE1A, OGG1 | PARP1 248/4885PARP2 196/4885MAP4K4 2674/4885 |
| US-20070270476-A1 | SUBSTITUTED 1H-BENZIMIDAZOLE-4-CARBOXAMIDES ARE POTENT PARP INHIBITORS | PARP1, PARP2, PARP4 | PARP1 1/4885PARP2 2/4885MAP4K4 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.